SLC5A2 and type 2 diabetes mellitus: There have not been any head-to-head clinical trials to evaluate the efficacy and safety of canagliflozin versus dapagliflozin in patients with T2DM, and, to date, the only head-to-head study of any SGLT2 inhibitors is a phase 1 study comparing the pharmacodynamic properties of canagliflozin 300 mg versus dapagliflozin 10 mg in healthy individuals [12].